Translating biomedical research from the laboratory to commercial applications is a time-consuming and expensive process. But efforts are underway to increase collaboration between scientists and speed medical advances, according to the "PBS Newshour."
In the segment, Stanford neurobiologist Ben Barres, MD, PhD, discusses bridging the gap between academia and private industry. Barres is engaged in a collaborative research effort funded by Myelin Repair Foundation to develop new multiple sclerosis treatments and to provide data to persuade drug companies to take the next step.
Stanford researchers are also working to make translational medicine a reality through the School of Medicine's SPARK program, which creates partnerships between scientists and entrepreneurs to promote innovative research.
Previously: Why drug development is time consuming and expensive (hint: it's hard)
